The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care.
Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.
By continuing an open discussion on precision medicine and precision care, we can truly accelerate pharmacogenomic testing to its full potential and focus on providing the highest quality care to those who need it most.
/PRNewswire/ Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health.